Difference between revisions of "Sekulic A, et al. N. Engl. J. Med. (2012) cited as Ref 599 in DOI: 10.1038/s41392-020-0110-5 (Q9862)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created claim: DOI Identifier (P138): 10.1056/NEJMoa1113713, #quickstatements; #temporary_batch_1590000649558)
(‎Created claim: Page(s) (P105): 2171-2179, #quickstatements; #temporary_batch_1590074839150)
 
(5 intermediate revisions by the same user not shown)
Property / PubMed ID
 +
Property / PubMed ID: 22670903 / rank
 +
Normal rank
Property / Publication Date
 +
2012
Timestamp+2012-01-01T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 year
Before0
After0
Property / Publication Date: 2012 / rank
 +
Normal rank
Property / Published In Name String
 +
N. Engl. J. Med.
Property / Published In Name String: N. Engl. J. Med. / rank
 +
Normal rank
Property / Volume
 +
366
Property / Volume: 366 / rank
 +
Normal rank
Property / title
 +
Efficacy and safety of vismodegib in advanced basal-cell carcinoma (English)
Property / title: Efficacy and safety of vismodegib in advanced basal-cell carcinoma (English) / rank
 +
Normal rank
Property / Page(s)
 +
2171-2179
Property / Page(s): 2171-2179 / rank
 +
Normal rank

Latest revision as of 15:46, 21 May 2020

Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language Label Description Also known as
English
Sekulic A, et al. N. Engl. J. Med. (2012) cited as Ref 599 in DOI: 10.1038/s41392-020-0110-5
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

    Statements

    Sekulic A
    0 references
    0 references
    2012
    0 references
    N. Engl. J. Med.
    0 references
    366
    0 references
    Efficacy and safety of vismodegib in advanced basal-cell carcinoma (English)
    0 references
    2171-2179
    0 references